Plus   Neg

Madrigal Pharmaceuticals Inc. (MDGL) Has Surged To A New High On Study Results

Madrigal Pharmaceuticals Inc. (MDGL) announced Wednesday morning that its Phase 2 trial of MGL-3196, in patients with biopsy-proven non-alcoholic steatohepatitis, met its primary endpoint.

Madrigal Pharmaceuticals gapped open sharply higher this morning and has spiked to the upside in early trade. Shares are now up 34.42 at $80.72 on above average volume. The stock has soared to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Intraday Alerts

0 Articles
Follow RTT